Bioanalytical bottleneck slowing GLP‑1 receptor agonist development
Despite the clinical successes of semaglutide and tirzepatide, many sponsors still encounter persistent bioanalytical challenges when translating GLP‑1 receptor agonists from discovery to clinic. Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) based assays are widely applied for the bioanalysis of GLP-1 receptor agonists because of their high specificity and reduced reliance on selective antibodies compared with ligand-binding assays. Large molecular size, strong non-specific binding, low plasma concentrations for non‑injectable formulations, and background interferences conspire to erode sensitivity, recovery, and specificity. These challenges can delay go/no‑go decisions, mislead PK/PD interpretation, and undermine formulation innovation such as oral or Fc‑fusion approaches.
Three Points to Address Bioanalytical Challenges
#1. Signal optimization
MRM transition selection.
For large peptides such as semaglutide, broad isotopic distributions and multiple charges would dilute MS response, and low m/z fragments would result in high background interferences. Prioritizing larger, more specific fragment ions that are less prone to interferences and produce stronger, more selective signals. In practice this means screening collision induced dissociation (CID) spectra for mid‑to‑high m/z fragments with strong intensity, and assessing background across blank matrices before choosing transitions.
Analyte enrichment.
After sample pretreatment with methods such as protein precipitation (PPT) or solid phase extraction (SPE), the sample volume usually increases, and target analyte is diluted, which leads to lower signal. Post‑extraction enrichment with evaporation and reconstitution is often applied. Reconstitution solvent composition should be tuned to improve ionization and peak shape. This process must also be implemented carefully to avoid loss or bias — recovery and matrix effects should be assessed at each step.
#2 Recovery Improvements
Peptide bioanalysis, especially those with fatty acid modifications, often faces recovery issues during PPT and/or SPE. If the drug remains bound to protein during cleanup, recovery will be poor and variable. Pretreatment that dissociates complexes prior to protein removal or SPE loading must be carried out.
For PPT, pretreatment reagents (e.g., acid/base adjustment, buffers, surfactants, or denaturants) can be used to liberate the peptide prior to addition of precipitant (such as methanol or trichloroacetic acid in water, etc.). Aim for loose precipitates that favor analyte release.
For SPE, optimize sorbent chemistry, loading conditions and elution profiles. When peptide–protein complexes slow permeation, include a dissociation step and allow sufficient contact time before loading. For non‑fluid matrices, homogenize into a homogeneous liquid prior to SPE. In some cases involving fatty‑acid–modified GLP‑1 analogues, implementation of a pre‑dissociation step followed by optimized SPE has markedly improved recoveries from ~1% to above 70%.
Moreover, recovery should be assessed at different concentration levels to ensure consistency.
#3. Carryover Reduction
GLP-1 receptor agonist peptides, especially those with fatty acid modifications, often have high carryover, which lowers sensitivity and may cause inaccuracy. Proper choice of LC system, selection of LC column type, adjustment of mobile phase pH and elution profile, and optimization of wash buffers can all contribute to lower carryover. For example, in one case for semaglutide bioanalysis, switching chromatography chemistry, such as changing RP columns to HILIC columns, can dramatically reduce analyte–stationary phase interactions. Strong, weak, and needle wash composition also greatly affect carryover. As a rule, maintain a library of column/wash combinations proven effective for sticky peptides.
